Thanks to the publication of new clinical practice guidelines from the American College of Cardiology, the American Heart Association and the Heart Failure Society of America.
The new guidelines are a great resource for doctors looking for the most up-to-date data to help care for their patients, given that the last comprehensive guideline was published nearly 10 years ago, says Salim Hayek, MDassistant professor of internal medicine and cardiologist at the University University of Michigan Frankel Cardiovascular Centerwho served on the editorial board.
Physicians caring for heart failure patients with and without reduced ejection fraction will find new recommendations in the guidelines regarding sodium-glucose-2 cotransporter, or SGLT, inhibitors.
“This class of drugs, originally intended for the treatment of diabetes, has proven to be an amazing therapy for patients with heart failure,” said Hayek. “Most importantly, they work well in patients with heart failure and preserved ejection fraction, a group of patients for whom effective treatments are lacking.”
Another key message is that specialist heart failure teams, such as Frankel HVAC offeringsare essential to assess patients with advanced heart failure and provide life-saving therapies, added a member of the guideline writing board Monica Colvin, MD, MSassociate director of the heart transplant program and heart failure and transplant cardiologist at Frankel CVC.
Reducing the prevalence of heart failure in the first stage is also of great importance: the stages of heart failure are revised to emphasize prevention for those at risk of heart failure or in pre- heart failure.
Additionally, economic analyzes are included for some treatments, with value statements to help clinicians and patients who decide to try something expensive. Only one treatment was defined as low value: tafamidis for cardiac amyloidosis.
And for the first time, the guideline offers recommendations for cardio-oncology, clinical guidance for Hayek, providing guidance on the management and prevention of cardiotoxicity related to cancer treatment.
It’s important to note the patient-centered approach of the new guideline, Hayek and Colvin added.
Guideline quoted: “2022 AHA/ACC/HFSA guideline for the management of heart failure: A report from the American College of Cardiology/American Heart Association Joint 4 Committee on Clinical Practice Guidelines.